The study was aimed at evaluating the efficacy and the tolerability of felbamate (FLB) in adult patients with refractory partial epilepsy. FLB was given as add-on therapy, according to a multicenter. randomized, double-blind, placebo-controlled trial. Eighty-three patients entered the study: one patient died 5 days after entering the trial because of the traumatic consequences of a seizure. FLB resulted significantly more effective than placebo in reducing the percentage of seizures; in 38% of patients treated with FLB a reduction of seizures greater than 50c/c was obtained and I ]c/r of them resulted seizure-free. Adverse experiences with FLB were generally considered mild or moderate and caused early discontinuation of treatment in only iwo cases (diplopia and lipothymie episodes, respectively). No clinically significant modification of laboratory parameters occurred during the trial.
|Number of pages||1|
|Journal||Italian Journal of Neurological Sciences|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Clinical Neurology